Imperial College London
Alternate

ProfessorCharlesCoombes

Faculty of Medicine, Department of Surgery & Cancer

Emeritus Professor of Medical Oncology
 
 
 
//

Contact

 

+44 (0)20 7594 2135c.coombes

 
 
//

Assistant

 

Mrs Suzy Ford +44 (0)20 7594 2135

 
//

Location

 

145ICTEM buildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Joseph:2019:10.1038/s41416-019-0589-0,
author = {Joseph, C and Al-Izzi, S and Alsaleem, M and Kurozumi, S and Toss, MS and Arshad, M and Goh, FQ and Alshankyty, IM and Aleskandarany, MA and Ali, S and Ellis, IO and Mongan, NP and Green, AR and Rakha, EA},
doi = {10.1038/s41416-019-0589-0},
journal = {British Journal of Cancer},
pages = {776--785},
title = {Retinoid X receptor gamma (RXRG) is an independent prognostic biomarker in ER-positive invasive breast cancer.},
url = {http://dx.doi.org/10.1038/s41416-019-0589-0},
volume = {121},
year = {2019}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BACKGROUND: Retinoid X Receptor Gamma (RXRG) is a member of the nuclear receptor superfamily and plays a role in tumour suppression. This study aims to explore the prognostic significance of RXRG in breast cancer. METHODS: Primary breast cancer tissue microarrays (n = 923) were immuno-stained for RXRG protein and correlated with clinicopathological features, and patient outcome. RESULTS: Nuclear RXRG expression was significantly associated with smaller tumour size (p = 0.036), lower grade (p < 0.001), lobular histology (p = 0.016), lower Nottingham Prognostic Index (p = 0.04) and longer breast cancer-specific survival (p < 0.001), and longer time to distant metastasis (p = 0.002). RXRG expression showed positive association with oestrogen receptor (ER)-related biomarkers: GATA3, FOXA1, STAT3 and MED7 (all p < 0.001) and a negative correlation with the Ki67 proliferation marker. Multivariate analysis demonstrated RXRG protein as an independent predictor of longer breast cancer-specific survival and distant metastasis-free survival. In the external validation cohorts, RXRG expression was associated with improved patients' outcome (p = 0.025). In ER-positive tumours, high expression of RXRG was associated with better patient outcome regardless of adjuvant systemic therapy. ER signalling pathway was the top predicted master regulator of RXRG protein expression (p = 0.005). CONCLUSION: This study provides evidence for the prognostic value of RXRG in breast cancer particularly the ER-positive tumours.
AU  - Joseph,C
AU  - Al-Izzi,S
AU  - Alsaleem,M
AU  - Kurozumi,S
AU  - Toss,MS
AU  - Arshad,M
AU  - Goh,FQ
AU  - Alshankyty,IM
AU  - Aleskandarany,MA
AU  - Ali,S
AU  - Ellis,IO
AU  - Mongan,NP
AU  - Green,AR
AU  - Rakha,EA
DO  - 10.1038/s41416-019-0589-0
EP  - 785
PY  - 2019///
SN  - 0007-0920
SP  - 776
TI  - Retinoid X receptor gamma (RXRG) is an independent prognostic biomarker in ER-positive invasive breast cancer.
T2  - British Journal of Cancer
UR  - http://dx.doi.org/10.1038/s41416-019-0589-0
UR  - https://www.ncbi.nlm.nih.gov/pubmed/31558802
UR  - https://www.nature.com/articles/s41416-019-0589-0
UR  - http://hdl.handle.net/10044/1/74984
VL  - 121
ER  -
Download